These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21674263)

  • 1. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect.
    Thombre AG; Herbig SM; Alderman JA
    Pharm Res; 2011 Dec; 28(12):3159-70. PubMed ID: 21674263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations.
    Thombre AG; Shah JC; Sagawa K; Caldwell WB
    Int J Pharm; 2012 May; 428(1-2):8-17. PubMed ID: 22349051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
    Dening TJ; Rao S; Thomas N; Prestidge CA
    Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state.
    Thombre AG; Caldwell WB; Friesen DT; McCray SB; Sutton SC
    Mol Pharm; 2012 Dec; 9(12):3526-34. PubMed ID: 23075293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect.
    Miao Y; Chen G; Ren L; Pingkai O
    Drug Deliv; 2016 Sep; 23(7):2163-2172. PubMed ID: 25148542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state.
    Yanfei M; Guoguang C; Lili R; Pingkai O
    Drug Dev Ind Pharm; 2015; 41(8):1353-62. PubMed ID: 25138348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
    Lincoln J; Stewart ME; Preskorn SH
    J Psychiatr Pract; 2010 Mar; 16(2):103-14. PubMed ID: 20511734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of food on the absorption of oral ziprasidone.
    Miceli JJ; Glue P; Alderman J; Wilner K
    Psychopharmacol Bull; 2007; 40(3):58-68. PubMed ID: 18007569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Release Ziprasidone Microparticles Prepared by Spray Drying with Soluplus® and Ethyl Cellulose to Eliminate Food Effect and Enhance Bioavailability.
    Liu W; Wang S; Lu W; Cheng Z; Jiang N
    AAPS PharmSciTech; 2019 Dec; 21(1):27. PubMed ID: 31858315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Combined Utilization of Plasdone-S630 and HPMCAS-HF in Ziprasidone Hydrochloride Solid Dispersion by Hot-Melt Extrusion to Enhance the Oral Bioavailability and No Food Effect.
    Xue X; Chen G; Xu X; Wang J; Wang J; Ren L
    AAPS PharmSciTech; 2019 Jan; 20(1):37. PubMed ID: 30604142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS).
    Christiansen ML; Holm R; Kristensen J; Kreilgaard M; Jacobsen J; Abrahamsson B; Müllertz A
    Eur J Pharm Sci; 2014 Jun; 57():164-72. PubMed ID: 24239996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption.
    Sutton SC; Nause R; Gandelman K
    AAPS J; 2017 Jul; 19(4):1084-1090. PubMed ID: 28321831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.
    Lindsay J; Mudge S; Thompson GR
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect.
    Miao Y; Chen G; Ren L; Ouyang P
    J Pharm Pharmacol; 2016 Feb; 68(2):185-94. PubMed ID: 26748446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.
    Gandelman K; Alderman JA; Glue P; Lombardo I; LaBadie RR; Versavel M; Preskorn SH
    J Clin Psychiatry; 2009 Jan; 70(1):58-62. PubMed ID: 19026256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fed and fasted state gastro-intestinal in vitro lipolysis: In vitro in vivo relations of a conventional tablet, a SNEDDS and a solidified SNEDDS.
    Christophersen PC; Christiansen ML; Holm R; Kristensen J; Jacobsen J; Abrahamsson B; Müllertz A
    Eur J Pharm Sci; 2014 Jun; 57():232-9. PubMed ID: 24056027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation development and systematic optimization of stabilized ziprasidone hydrochloride capsules devoid of any food effect.
    Banerjee S; Shankar KR; Prasad Y R
    Pharm Dev Technol; 2016 Nov; 21(7):775-786. PubMed ID: 26135230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug-Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models.
    Wagner C; Kesisoglou F; Pepin XJH; Parrott N; Emami Riedmaier A
    AAPS J; 2021 Jun; 23(4):85. PubMed ID: 34142242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile.
    Stip E; Zhornitsky S; Moteshafi H; Létourneau G; Stikarovska I; Potvin S; Tourjman V
    Clin Ther; 2011 Dec; 33(12):1853-67. PubMed ID: 22133697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules.
    Curatolo W; Liu P; Johnson BA; Hausberger A; Quan E; Vendola T; Vatsaraj N; Foulds G; Vincent J; Chandra R
    Pharm Res; 2011 Jul; 28(7):1531-9. PubMed ID: 21331473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.